- $4.17bn
- $4.35bn
- $1.08bn
NYSE ORDER IMBALANCE 136163.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 168833.0 SHARES ON SELL SIDE
Cactus Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cactus Announces First Quarter 2022 Results
Cactus Inc expected to post earnings of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Astec Industries, ChampionX, Schlumberger NV
NYSE ORDER IMBALANCE 51125.0 SHARES ON BUY SIDE
Brief: Cactus Inc Files For Mixed Shelf Size Not Disclosed
Cactus Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cactus Announces Fourth Quarter And Full Year 2021 Results
NYSE ORDER IMBALANCE 54881.0 SHARES ON SELL SIDE
Cactus Inc expected to post earnings of 20 cents a share - Earnings Preview
Brief: Cactus Announces Quarterly Cash Dividend Increase
U.S. RESEARCH ROUNDUP-Amicus Therapeutics, Five Below, ResMed
Cactus Inc reports results for the quarter ended in September - Earnings Summary
Brief: Cactus Announces Third Quarter 2021 Results
Cactus Inc expected to post earnings of 19 cents a share - Earnings Preview
NYSE ORDER IMBALANCE 214676.0 SHARES ON BUY SIDE
Brief: Cactus And Nesr Announce Collaboration In The Middle East